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Abstract

The atypical cellular blue nevus is an extremely rare nevomelanocytic lesion which lacks precise
histologic characterization in the current literature. Given the potential for significant architectural and
cytologic overlap with melanoma, further study, including molecular analysis, is needed. This is the first
description of an atypical cellular blue nevus of the oral cavity.
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Introduction

The cellular blue nevus (CBN) is a well-characterized benign, acquired dermal melanocytic tumor1, 2.
While clinically indistinguishable from the common blue nevus3, it is microscopically distinguished by a
biphasic proliferation of hypercellular, nodular aggregates of tumor cells which often lie deep to a
typical blue nevus. The border shows well-demarcated tumor nodules with rare infiltration and a
notably absent host inflammatory response. The cellular portion contains ovoid to spindle-shaped
melanocytes with small nucleoli and variable pigmentation2, 3. Mitotic activity can be seen
(≤2 mitoses/mm2) while necrosis as well as junctional activity or epidermal invasion are typically
absent2, 4. Following conservative excision, long-term follow-up data indicate a very small risk for
recurrence and no metastasis2. In the oral cavity, common blue nevi are occasionally seen 5, while
cellular blue nevi are exceedingly rare, with only 2 reported cases6, 7.
In some instances, a blue nevus (most often CBN) is associated with a malignant melanoma and is
referred to as malignant blue nevus (MBN), blue nevus-like melanoma or malignant melanoma arising
in a blue nevus4, 8–14. When unquestionably malignant features such as widespread necrosis, mitotic
activity, atypical mitoses and marked cytologic atypia are juxtaposed next to an otherwise bland CBN,
the diagnosis is straightforward. However, multiple reports in recent decades of tumors with features
intermediate between CBN and MBN prompted the controversial15 designation of “atypical blue
nevus” or “atypical cellular blue nevus” (ACBN)16, 17. While similar clinically and apparently biologically
to CBN17, discrete histologic criteria for ACBN are currently under debate even among expert
dermatopathologists18–22. The most often cited histologic criteria include asymmetry, a deeply
infiltrative and irregular border, mild cytologic atypia, and mitotic activity >2 mm2 17, 18, 23. Herein we
describe, to our knowledge, the first oral case of a CBN exhibiting atypical architectural features along
with complementary molecular data.

Case Report

A 46-year-old white male presented with a mass of undetermined duration on his right buccal mucosa.
The patient’s past medical history was non-contributory. Extraoral examination was within normal
limits. Intraorally, an exophytic, red-blue, firm, sessile nodule measuring approximately
17 × 15 × 12 mm was noted on the right buccal mucosa adjacent to the grossly decayed crown of the
maxillary third molar. A working diagnosis of a fibroma or a pyogenic granuloma was given. The lesion
was surgically excised and submitted for histopathological examination.
Microscopic examination of tissue sections showed an attenuated surface epithelium overlying a
neoplasm of nevomelanocytic differentiation. The lesion was poorly circumscribed and asymmetrical
with variable intense melanin production. The lesional growth pattern included diffuse sheets of cells,
small nests and islands, and strands of cells, all set within a moderately dense collagenous stroma
(Fig. 1). Superficially, the organoid and theque-forming lesional cells showed intimate association with
the basal layer, including some junctional activity, but with no evidence of intraepithelial spread
(Fig. 2). The superficial lesional cells had a characteristic nevocytic as well as spindled morphology and

scattered nevus giant cells were seen (Fig. 3). More deeply, the biphasic architecture characteristic of
CBN was noted (Fig. 4). Within the cellular nodules, the cells were fusiform to oval with indistinct
cytoplasmic membranes enclosing moderate amounts of amphophilic cytoplasm. Lesional cell nuclei
were round to oval with vesiculated chromatin and a single prominent eosinophilic nucleolus (Fig. 5a)
or intranuclear vacuoles (Fig. 5b). The tumor cells were diffusely infiltrative within the deeper skeletal
muscle bundles (Fig. 6) and extended as variably sized-nests into underlying fat (Fig. 7). Tumor was
transected at the lateral and deep margins. Mitotic figures and pleomorphism were not seen, and
there was no evidence of necrosis or a significant host inflammatory response to the tumor. On the
basis of the features described, a histopathologic diagnosis of “CBN with architectural atypia” was
made. After over 4 years without evidence of local recurrence, our patient was lost to follow-up.

Fig. 1 The tumor is unencapsulated with an infiltrative growth pattern. Lesional cells exhibit sheet-like, nested
and strand-like growth pattern. Melanin deposition is highly variable

Fig. 2 Organoid and theque forming cells are intimately associated with the epithelium. There is no
intraepithelial involvement

Fig. 3 Subepithelial lesional cells show nevocytic and epithelioid morphology. Scattered nevus giant cells are also
seen

Fig. 4 Biphasic appearance: dense fibrous connective tissue containing dendritic melanocytes and melanophages
typical of common blue nevus on the right and cellular nodules of cellular blue nevus on the left

Fig. 5 Tumor cells have indistinct cytoplasmic membranes enclosing amphophilic cytoplasm and contain
vesiculated nuclei with a single prominent eosinophilic nucleolus (a). Many nuclei show intranuclear inclusionlike vacuolation (b)

Fig. 6 Diffuse insinuation of lesional tissue between skeletal muscle fiber bundles

Fig. 7 Extension of small and large tumor nests into underlying fat
Immunohistochemistry was performed using antibodies to soluble adenylyl cyclase (sAC) according to a
previously published procedure24. In brief, the R21 is a mouse monoclonal antibody directed against amino acids
203–216 of human sACfl protein. This antibody was provided to us by the laboratory of Lonny Levin and Jochen
Buck. The primary antibody (3 mg/mL) was applied for 25 min in a buffered Primary Antibody Diluent (AR9352)
from Leica Microsystems. The optimal dilution was determined to be 1:1200. Following this step, the sections
were treated by a post primary AP step for 20 min for signal amplification as part of the procedure detailed in
the Leica Microsystems Bond Polymer AP Red Detection kit (part number DS9305). The amplification polymer
was then added for 30 min followed by two washes in wash buffer and one wash in deionized water. Finally, the
mixed red substrate was applied for 10 min, followed by an additional 10 min with new substrate, three washes

in deionized water only, and, finally, mounting with a coverslip. The sAC pattern exhibited a variable pattern
comprising perinuclear golgi, incomplete granular nuclear and pan nuclear staining (Fig. 8). The cells exhibiting a
pan nuclear staining pattern showed the greatest extent of atypia and this feature was most apparent in areas
of cellular fascicular growth.

Fig. 8 Immunohistochemistry for sAC antibody (see letters): a The dominant pattern is characterized by

perinuclear broad golgi and or b weak diffuse cytoplasmic staining. Some cells exhibit either a c pan nuclear and
or d incomplete granular nuclear staining pattern typical for borderline tumors; the extent of pan nuclear
staining is not as great as that seen in classic melanoma

Fluorescence in situ hybridization targeting 6p25 (RREB1), 6q23 (MYB), and 11q13 (cyclin D1), and
Cep6 was performed based on a previously published study25 which provided validation that this
particular set of probes was useful in the distinction of melanoma from a benign nevus. Fluorescent in
situ hybridization (FISH) was performed using the Abbott melanoma FISH test (Abbott Park, Illinois).
Positive results were defined as 1) a gain in 6p25 (RREB1) relative to CEP6 greater than 55 %, a 2) gain
in 6p25 (RREB1) greater than 29 % a 3) loss in 6q23 (MYB) relative to CEP6 greater than 40 % or a 4)
gain in 11q13 (CCND1) greater than 38 %. Our analysis revealed that the CCND1 and RREB1 probes
showed no amplification. There was no loss of MYB.

Discussion

The group of lesions characterized as “atypical cellular blue nevus” falls into a category that some have
referred as “melanocytic tumor of uncertain malignant potential (MELTUMP)20, 21, 23.” This designation
derives from the diagnostic difficulty in classifying these lesions as benign or malignant. Some believe
that this group represents low-grade tumors with potential for lymph node metastasis but rare distant
metastasis20. The topic of ACBN has drawn considerable attention in the last several years given the
struggle among experts to agree upon strict clinical and histologic criteria18–21. For instance, when 14
dermatopathologists used a defined set of criteria to discriminate CBN from ACBN and MBN only
18.2 % of the ACBN lesions were correctly identified by the majority of the pathologist 18. The authors
concluded that histologic overlap makes it difficult to define the “limits of atypicality” for a diagnosis of
ACBN over CBN as well as to establish the minimal criteria to warrant a malignant diagnosis. These
challenges are reiterated in the most recent literature19–21. Some contend that this intermediate
designation should be eliminated in favor of just CBN or melanoma in association with a blue nevus15.
They suggest that if the expected biologic behavior is in question, a consultative second opinion should
be procured or that complete excision is advised. Similarly, other authors suggest that ACBN is likely

not a distinct entity, but rather a group of lesions that are either CBN with atypical histologic features
(will behave in an indolent fashion) or CBN-like low grade melanoma19. While the quest for a simple
dichotomous classification is desirable, it is likely that atypical lesions fall within a biologic continuum
between benign and malignant26. Certainly, further study leading to more precise diagnostic criteria is
necessary, with hope that molecular methods may help to stratify these histologic uncertainties into
benign (nevus) or malignant (melanoma)19–21. Herein, we compare our case to the previously reported
clinical and histologic criteria for ACBN as it relates to CBN and MBN. For a specific discussion on the
histologic differential diagnosis with other lesions sharing some features of ACBN (e.g. epithelioid blue
nevus, deep penetrating nevus) the reader is referred to several recent reviews3, 19, 20, 22.
While comparisons of the clinical presentations of CBN, ACBN and MBN have not yielded clearly
distinctive features, some trends have been noted. A summary by Tran et al.17 indicates that CBN tend
to occur at a younger average age (32.6 years) versus ACBN (37 years) and MBN (48.8 years).
Evaluation of their ACBN case series (N = 9) alone yielded an average age of 47.4 years; similar to our
case. The CBN occur on the buttocks/lumbosacral region followed by the scalp, face and hand2, 23.
ACBN cases similarly affect the buttocks, scalp and the extremities16, 17, 27 while MBN have somewhat
greater propensity to affect the scalp11. Women are affected more often than men for CBN and ACBN
whereas MBN affects men more frequently1, 17 but these differences are modest. Hence, neither
location nor gender are particularly distinctive in our case.
While many authors report that increasing size is more often associated with atypical or malignant
lesions, there is disagreement over precise values. Cutoffs for distinguishing ACBN from CBN varies
from >1–2 cm17, 18 to >2–3 cm22 to >5 cm3. As the size increases from >3 cm23 to >6 cm3, melanoma is
reported to be more likely. Lesions falling within the 1–2 cm range (our case was 1.7 cm) have been
reported for CBN2, 4 as well as for MBN9 such that size is not discriminatory in our case.
As previously mentioned, defining histologic criteria for ACBN is difficult. While CBN are typically
symmetrical with well-circumscribed nodules2, 23, ACBN are often characterized by asymmetry17, 18,
deep extension into subcutaneous tissue3, and an infiltrating border3, 17. Our case exhibited an
asymmetric (Fig. 1) and infiltrating border (Fig. 7), and deep extension through muscle and fat. While
CBN are dermal-based tumors lacking an epidermal or junctional component, our case exhibited tumor
cells that often intermingled with the surface epithelium and showed focal junctional activity (Fig. 2).
No intraepithelial spread suggestive of melanoma was identified. Only once has epidermal involvement
been reported in an ACBN, wherein an overlying junctional nevus was identified17.
Cytologic characteristics cited in early reports of ACBN were thought to be distinctive for this entity.
Specifically, cellular pleomorphism, numerous bizarre and heavily pigmented multinucleated cells and
giant cells16, 27 as well as atypical and mostly nonpigmented cells with hyperchromatic nuclei were
reported27. Only a “few mitoses” were reported in 1 of the 5 cases from these 2 studies. Of the 9 cases
reported by Tran et. al.17, seven showed abnormal cytologic features: nuclear pleomorphism,
hyperchromatism, bizarre cells, high nuclear/cytoplasmic ratio and mitotic activity (1–2 mm2 in 5
cases), particularly at the deeper aspect. The authors did not consider these features as malignant,
reserving “marked cytologic atypia”, atypical mitoses, necrosis, and marked histologic heterogeneity as
characteristic of MBN17. While rare to absent in CBN 2, mitotic activity is nearly always seen in MBN10,
11, though at a variable rate. While mitotic rates often overlap in ACBN and MBN8, 18, 19, 22, the presence

of mitotic activity in atypical blue nevi is associated with unfavorable biologic behavior21 and multiple
groups have reported that atypical mitoses are a feature of malignancy4, 9, 11, 13, 28. Our case lacked
atypical cytologic features as may occur in ACBN. Atypical mitotic activity was also absent, suggesting a
more indolent biologic potential. As such, the diagnosis of ACBN rendered in this case rests on the
atypical architectural features, which is within the spectrum previously described in these lesions.
Other important features include necrosis and host inflammation. While necrosis may be seen in MBN,
it is not observed in the majority of cases9, 11, 14, though other groups report that it is invariably found29.
Necrosis has been reported in some cases of ACBN17 and in a small percent of CBN4. Therefore, while
necrosis suggests a more aggressive process, it is not entirely specific for malignancy. Lastly,
inflammation is frequently noted at the periphery of melanomas but is typically absent in CBN2.
Inflammation in MBN is highly variable9, 11 and in the 14 well-documented cases of ACBN it was seen in
10 (71 %), with 6 showing only a “mild” reaction16, 17, 27. Our case lacked necrosis or a significant
inflammatory response, both indicating a less aggressive process.
Given the challenge of defining ACBN histologically, hopes have been raised that molecular techniques
may help provide distinction19–21. Building on initial data using comparative genomic hybridization, a 4probe fluorescent in situ hybridization (FISH) assay (Abbott melanoma FISH test, Abbott Park, Illinois)
was developed to assist in separating benign and malignant melanocytic lesions, with particular
emphasis on histologically ambiguous cases25, 30, 31. Most recently, this technique was specifically used
to try to distinguish CBN from CBN with atypical features32. A positive result was found in 5 blue nevuslike melanomas and was negative in 17 cases of CBN. Assessment of certain cytogenetic abnormalities
encountered in melanoma is another important diagnostic adjunct that was applied in this case. We
did not observe any of the cytogenetic abnormalities potentially encountered in melanoma; in
particular we were unable to detect abnormalities in RREB1, MYB, and CCND1.
The antibody to sAC has emerged as another important diagnostic adjunct in the assessment of
melanocytic lesions24. A discriminatory staining pattern is observed that separates benign melanocytic
proliferations from melanoma. In borderline tumors, an intermediate pattern between the perinuclear
dot-like golgi pattern of a benign nevus to one of frank pan nuclear staining is observed. Indeed in our
case the sAC profile was variable and included foci of enhanced nuclear staining in areas of severe
atypia. However, in the majority of lesional cells the staining pattern was not pan nuclear but was
dominated by an incomplete granular nuclear and perinuclear staining pattern. While this approach
has not been applied to a large number of ACBN cases, it may prove to be a promising adjunctive
technique in the evaluation of atypical melanocytic lesions33.
Perhaps the most useful criterion for the accurate classification of these lesions is assessment of
biologic behavior. Cases of CBN rarely recur and do not metastasize2 while MBN often recur,
metastasize and frequently lead to death9–11. The intermediate designation of ACBN has drawn some
criticism15 due to the fact that, of the well-characterized cases, only one has recurred and none have
metastasized16, 17, 27. The follow-up period varied tremendously in these cases from 12 to 228 months
with an average of nearly 59 months. While most MBN metastasize within 1–2 years1, 8, 11, 13, there are
5 reports of delayed metastasis from 5 to 19 years after initial surgery11, 34–36, suggesting that
malignancy cannot be ruled out in a small percent of cases without extensive follow-up. In our case,
tumor was transected at the deep and lateral surgical margins, potentially predisposing to regrowth23,

37.

Yet the patient refused reexcision, and after 4 years without recurrence, he was lost to follow-up.
No report of lymphadenopathy was given by the surgeon in our case. Compared to reported studies,
this significant follow-up period would suggest a favorable course.

Despite the ongoing debate, most investigators currently consider ACBN as a low-grade malignant
melanocytic tumor with the potential for spread to regional lymph nodes and rare distant metastasis18,
20, 21. Most authors currently recommend complete surgical excision10, 11, 19, 21, 37 with assured clear
histologic margins20. While some advocate reasonably extending the surgical margins up to 1 cm21,
there is no consensus at this point if this is appropriate until further study of these unusual tumors
occurs20.
In this report, we document the first complete description of an atypical CBN of the oral cavity. While
cytologically bland, the atypical architectural features are sufficient to warrant this diagnosis. Based on
4 years of follow-up without regrowth of the incompletely excised lesion, along with molecular data, a
good prognosis is likely.
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